Summit Therapeutics Inc. (SMMT)
XMEX 
NASDAQ (NMS) Primary XMEX Summary
SMMT Chart
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet
Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short squeeze to take place. Recent pullbacks, driven by mixed market receptions to events do not fundamentally alter the investment narratives, present investors with an attractive entry point ahead of key catalysts.
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Summit Therapeutics Inc. (SMMT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Summit Therapeutics Inc. ever had a stock split?
Summit Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robert W. Duggan CEO | XMEX Exchange | US86627T1088 ISIN |
| US Country | 265 Employees | - Last Dividend | - Last Split | 5 Mar 2015 IPO Date |
Overview
Summit Therapeutics Inc. stands as a pioneering entity within the biopharmaceutical industry, dedicating its efforts toward the discovery, development, and commercialization of innovative therapeutic solutions. With a mission to cater to the needs of patients, physicians, caregivers, and society at large, the company has established a significant presence in both the United States and the United Kingdom. Since its inception in 2003, with its headquarters in Miami, Florida, Summit Therapeutics has been at the forefront of addressing some of the most challenging medical conditions by advancing a pipeline of promising drug candidates. The collaboration and license agreement with Akeso, Inc. and its affiliates specifically for the development and commercialization of ivonescimab highlights the company's strategy to leverage partnerships in realizing its vision.
Products and Services
- Ivonescimab
- SMT-738
This lead development candidate exemplifies Summit Therapeutics' focus on groundbreaking immunotherapy approaches. Ivonescimab is a bispecific antibody designed to block PD-1, enhancing the immune system's ability to fight cancer, while also targeting anti-angiogenesis, which is the process of cutting off the blood supply to tumors. This dual mechanism of action positions ivonescimab as a potentially powerful treatment for various cancers, reflecting Summit's commitment to advancing cancer treatment.
Under its portfolio of anti-infectives, Summit Therapeutics is developing SMT-738, a novel class of precision antibiotics aimed at combating multidrug-resistant infections, with a primary focus on tackling carbapenem-resistant Enterobacteriaceae (CRE) infections. The increasing prevalence of antibiotic-resistant infections represents a significant threat to public health, and SMT-738 is at the forefront of Summit's effort to develop effective treatments for these challenging conditions. By focusing on precision antibiotics, Summit aims to deliver treatments that are not only effective against pathogens but also minimize the impact on the body's beneficial bacteria, thus offering a groundbreaking approach to tackling antibiotic resistance.
